Трудности диагностики детского мультисистемного воспалительного синдрома, ассоциированного с COVID-19, в сочетании с ранней стадией первичной инфекции, вызванной вирусом Эпштейна-Барр

Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 is a rare life-threatening immunopathological complication of COVID-19 that develops 1-6 weeks after the acute coronavirus infection. MIS-C is characterized by fever and multiorgan inflammation.We present a clinical case of a 10-year-old boy with skin lesions at the onset of MIS-C (erythematous malar rash, lacelike rash on the trunk and extremities and petechiae) with macrophage activation syndrome development and the early stage of primary Epstein-Barr virus infection (EBV infection) which required the exclusion of X-linked lymphoproliferative disease.This clinical case demonstrates the complexity of diagnosis in MIS-C with skin manifestations at the onset of the disease, especially with concurrent activation of other infections, particularly EBV infection.Детский мультисистемный воспалительный синдром (ДМВС), ассоциированный с COVID-19 — это редкое жизнеугрожающее иммунопатологическое осложнение, развивающееся через 1-6 недель после перенесенной новой коронавирусной инфекции, протекающее с лихорадкой и мультиорганным воспалением.В статье представлено клиническое наблюдение мальчика в возрасте 10 лет с поражением кожи в дебюте ДМВС в виде полиморфной сыпи (эритема на щеках, сыпь в виде кружевного рисунка на туловище и конечностях, петехии), с одновременным обнаружением маркеров ранней стадии первичной инфекции, вызванной вирусом Эпштейна-Барр (ЭБВ), а также развитием гемофагоцитарного синдрома, что потребовало исключения Х-сцепленного лимфопролиферативного синдрома.Данное клиническое наблюдение демонстрирует сложность диагностического поиска при кожных проявлениях в дебюте ДМВС, а также возможность сочетания ДМВС с другими инфекциями, в частности с ЭБВ-инфекцией

OUTPATIENT MANAGEMENT OF A PATIENT WITH BECKWITHWIEDEMANN SYNDROME (CASE REPORT)

Beckwith - Wiedemann syndrome (ICD-10 code: Q 87.3) is a congenital disease characterized by macrosomia, macroglossia, hernia umbilical cord, overgrowth in the first few years of life, asymmetry of the body and a predisposition to embryonal tumor development. The disease was first described by American pathologist J.V. Beckwith in 1963 and, independently of him, by the German pediatrician H.R. Wiedemann in 1964. Thereafter, it was named the Beckwith-Wiedemann syndrome to honor of these scientists [1--4]

Semi-interpenetrating polymer networks based on polyurethane and poly(2-hydroxyethyl methacrylate): Dielectric study of relaxation behavior

International audienceThe study of molecular dynamics by broadband dielectric spectroscopy (BDS) is presented for polyurethane (PU), poly(2-hydroxyethyl methacrylate) (PHEMA) and for semi-IPNs based on PU and PHEMA synthesized by photopolymerization. The dielectric properties were performed in wide range of frequencies and temperatures with the goal to establish the relation between the relaxations and the structure. Five relaxation phenomena were finally detected for PHEMA : gamma-, beta sw-, beta-relaxations at low temperatures and a-relaxation at 150 degrees C at high frequencies plus ionic conductivity relaxation which starts at 0 degrees C. For semi-IPNs the overlapping of gamma- and beta sw-relaxations of PHEMA (-125/-75 degrees C) then with increasing the temperature alpha-relaxation in PU (-75/0 degrees C), next ionic conductivity relaxation which starts at 0 degrees C, and finally the alpha-relaxation of PHEMA (+125/+170 degrees C) were detected. The alpha-relaxation of PHEMA in semi-IPNs shifts to lower temperatures and became broader with increasing amount of PU due to incomplete phase separation in the system and formation of interphases. The dielectric relaxation phenomena were fitted with Havriliak-Negami equation. Activation energy, tau(o) and alpha parameters were calculated. For alpha-relaxations corresponding dielectric characteristics have been determined from Vogel-Fulcher-Tammann equation. The relaxation map for investigated PU, PHEMA and semi-IPNs was built

Synthesis and biological evaluation of a polyglutamic acid-dopamine conjugate: a new antiangiogenic agent

Dopamine has previously been shown to inhibit angiogenesis in vitro and in vivo, but its clinical applications in this context are severely limited by its short half-life. Here we report the synthesis of a polyglutamic acid-dopamine conjugate and show that conjugation significantly extends (from 1 to 24 h) dopamine’s antiangiogenic activity in vitro and in vivo. These findings form the basis for the development of a new class of agents for the treatment of angiogenesis-dependent diseases